IL6 and keloid: Furthermore, treatment of keloid fibroblasts with tocilizumab inhibited the ability to remodel and align the ECM while treatment of normal fibroblasts with IL-6 increased ECM alignment revealing that IL-6 is both necessary and sufficient to induce fibroblast remodeling to align the ECM (Fig. 9E–H).